CRVS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Corvus Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Pipeline Update on Soquelitinib

Nov 5, 2026

8-K

Corvus Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026

8-K

Corvus Pharmaceuticals Announces Resignation of Director Ian T. Clark

Jul 22, 2026

8-K

Corvus Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 12, 2026

8-K

Corvus Pharmaceuticals Presents Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis

May 14, 2026

8-K

Corvus Pharmaceuticals Reports Q1 2026 Financial Results and Provides Business Update on Soquelitinib Clinical Programs

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

March 2026 ATM | Offering amount: $200,000,000 | Shares: 11,834,319 | Bank: Jefferies LLC

Mar 13, 2026

424B5

REGISTERED OFFERING

Jan 23, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: Jefferies

Jan 20, 2026

424B5

SHELF OFFERING | Shares amount: 17,656,784 | Share price: $1.73 | Warrants amount: 17,089,436 | Warrants exercise price: $3.50

May 3, 2024

424B5

ATM | Offering amount: $40,000,000

Nov 2, 2021

424B5

Common Stock-

Feb 12, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 7, 2026

S-3ASR

March 2026 SHELF

Mar 13, 2026

S-3MEF

January 2026 SHELF

Jan 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

S-3

SHELF | ATM | Offering amount: $200,000,000.00 EFFECTIVE

Aug 6, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 7, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

STATE STREET CORP (Filed by)

Aug 7, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 27, 2026

Moore David Scott (Reporting)

Jun 15, 2026

CLARK IAN T (Reporting)

Jun 15, 2026

Grais Linda (Reporting)

Jun 15, 2026

Thompson Peter A. (Reporting)

Jun 15, 2026

Other

TYPE

HEADLINE

FILED AT

Corvus Pharmaceuticals, Inc. CRVS · SEC Filings